Aegis Life starts Entos DNA COVID-19 vaccine clinical trial

By The Science Advisory Board staff writers

April 19, 2021 -- Aegis Life, subsidiary of Entos Pharmaceuticals, has begun a phase I/II clinical trial of Entos' Covigenix VAX-001, a DNA COVID-19 vaccine.

The vaccine candidate "encodes the SARS-CoV-2 Spike (S) protein and uses novel Fusogenix technology for delivery," Aegis Life said. The next-generation gene delivery technology delivers DNA information inside cells, which is needed to make the viral protein for VAX-001 work. The trial is being conducted at the Canadian Center for Vaccinology and the IWK Health Centre, both in Halifax, Nova Scotia.

A participant receives a dose marking the start of phase I trials for Aegis Life/Entos Pharmaceuticals
A participant receives a dose marking the start of phase I trials for Aegis Life/Entos Pharmaceuticals' COVID-19 DNA vaccine, Covigenix VAX-001. Image courtesy of Aegis Life.

The two firms have also developed a second vaccine candidate, Covigenix VAX-002, which is now in preclinical studies and is intended as a pancoronavirus and emerging variant vaccine, they said.


Copyright © 2021 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?